Skip to content

Non-invasive Current Stimulation for Restoration of Vision

Non-invasive Current Stimulation for Restoration of Vision (REVIS) After Unilateral Occipital Stroke

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04008589
Enrollment
45
Registered
2019-07-05
Start date
2014-01-01
Completion date
2020-11-05
Last updated
2020-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Electrical Stimulation, Stroke

Brief summary

The aim of the study is to evaluate effects of current stimulation of the brain on vision parameters, vision-related quality of life, and physiological parameters to uncover mechanisms of vision restoration. These include EEG-spectra and coherence measures, and visual evoked potentials. The design of stimulation protocols involves an appropriate sham-stimulation condition and sufficient follow-up periods to test whether the effects are stable. This is the first application of non-invasive current stimulation for vision rehabilitation in stroke-related visual field deficits.

Interventions

DEVICErepetitive transorbital AC Stimulation

Repetitive transorbital ACS with max 30 Hz, 1,5 mA for 10 days, 20 min/day

DEVICEcombination of transcranial direct current stimulaton and rtACS

Sequential tDCS (anodal occipital stimulation with 2 mA for 20 min/day for 10 days) and rtACS

Sponsors

ERA-NET
CollaboratorUNKNOWN
University of Magdeburg
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Intervention model description

randomized, controlled

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* HH due to ischemic or hemorrhagic stroke * age between 18 and 75 years * lesion age at least 6 months * stable visual field defect across baseline measurement (subjects with spontaneous fluctuations and recovery of vision excluded) * presence of residual vision and detectable gradual transition between the intact and the absolutely blind part of the visual field according to evaluation of the clinician * best corrected visual acuity at least 0.4 (20/50 Snellen) or better

Exclusion criteria

* known active malignancy * eye or central nervous system diseases that interfere with the study (including poorly controlled glaucoma) * electric or electronic implants (e.g. heart pacemaker) * metal artifacts in the eyes or head (with the exception of dental prosthesis or shunts) * expected low compliance (e.g. in case of known psychiatric disease, known drug abuse, and dementing syndromes) * epileptic seizure within the last 10 years * use of antiepileptic or sedative drugs

Design outcomes

Primary

MeasureTime frameDescription
Size of the visual field2 weeksMean threshold in standard static perimetry and and detection accuracy in HRP

Secondary

MeasureTime frameDescription
Resting EEG power spectra2 weeksEEG measurement using 128 channel

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026